



# TIMI 37A

Protocol Design



Dose-ranging trial of the PARP inhibitor INO-1001 to ↓ reperfusion injury

**STEMI within 12h  
w/ planned 1° PCI**

N = 40

**INO-1001\***  
**IVB x 1**

ASA      Standard Rx

**RANDOMIZE (3:1)**  
**Single-blind**

**CONTROL**  
**IVB x 1**

**Primary  
PCI**

**Samples for  
PK/PD/Biomarkers**

**F/U at  
14 & 30 days**

Endpoints/Measures  
Pharmacokinetics  
Pharmacodynamics  
CK-MB, cTn, BNP  
Death/CHF/dysrhythmia

**\*Dose Escalation**

**Dose #1 x 1 (N = 10)**

**Dose #2 x 1 (N = 10)**

**Dose #3 x 1 (N = 10)**



# TIMI 37A

## Results

